Ascor

Dosage Forms & Strengths

tablets

• 100mg
• 250mg
• 500mg
• 1g

chewable, tablet

• 100mg
• 250mg
• 500mg

capsule, extended release

• 500mg

tablet, extended release

• 500mg
• 1000mg
• 1500mg

crystals

• 120g
• 480g

granules

• 100g
• 500g
• 1000g

injectable solution

• 250mg/mL
• 500mg/mL

oral solution

• 100mg/mL

powder effervescent

• 150g

powder, oral

• 113mg
• 120mg
• 480mg

water, oral

• 500mg

syrup, oral

• 100mg/mL

RDA

Males: 90 mg/day

Females: 75 mg/day

Pregnant: 85 mg/day; not to exceed 2000 mg/day (80 mg if <18 years; not to exceed 1800 mg/day)

Nursing: 120 mg/day; not to exceed 2000 mg/day (115 mg if <18 years old; not to exceed 1800 mg/day)

Urinary Acidification

4-12 g/day PO/IV divided three or four times daily

Ascorbic Acid Deficiency (Scurvy)

Oral prevention: See recommended daily intake

Oral treatment: 250 mg PO QID x 1 week

Treatment with IV ascorbic acid

• Indicated for short term (<1 week) treatment of scurvy in adult and children ≥5 months for whom oral administration is not possible, insufficient, or contraindicated
• 200 mg IV qDay; recommended daily treatment should not exceed 7 days
• If no improvement in scorbutic symptoms, retreat until resolution of scorbutic symptoms is observed
• Also, see Administration

Charcot-Marie-Tooth Disease (Orphan)

Designated orphan indication for Charcot-Marie-Tooth disease type 1A

Orphan designated sponsor

• Murigenetics SAS; Faculte de Medecine Timone; 13005 Marseille, France

Macular Degeneration (Off-label)

500 mg/day PO with other vitamins and minerals

Dosing Consideration

Use with caution in patients with renal impairment (see Warnings)

Limitations of use

• Ascor is not indicated for treatment of vitamin C deficiency that is not associated with signs and symptoms of scurvy

Dosage Forms & Strengths

tablets

• 100mg
• 250mg
• 500mg
• 1g

chewable, tablet

• 100mg
• 250mg
• 500mg

capsule, extended release

• 500mg

tablet, extended release

• 500mg1000mg1500mg

crystals

• 120g
• 480g

granules

• 100g
• 500g
• 1000g

injectable solution

• 250mg/mL
• 500mg/mL

oral solution

• 100mg/mL

powder effervescent

• 150g

powder, oral

• 113mg
• 120mg
• 480mg

water, oral

• 500mg

syrup, oral

• 100mg/mL

RDA

0-6 months: 40 mg/day

6-12 months: 50 mg/day

1-3 years: 15 mg/day

3-8 years: 25 mg/day

8-13 years: 45 mg/day

13-18 years: (male) 75 mg/day; (female) 65 mg/day

UL: 1-3 years: 400 mg/day; 4-8 years old: 600 mg/day; 9-13 years old: 1.2 g/day; 12-18 years old: 1.8 g/day

Urinary Acidification

500 mg/day divided PO/IV TID/QID

Ascorbic Acid Deficiency (Scurvy)

Oral prevention: See recommended daily intake

Oral treatment, infants or children: 100 mg PO TID x 1 week, then 100 mg PO qDay until resolved (typically 1-3 months)

Treatment with IV ascorbic acid

• Indicated for short term (<1 week) treatment of scurvy in children and adolescents ≥5 months for whom oral administration is not possible, insufficient or contraindicated
• <5 months: Safety and efficacy not established
• 5 months to <12 months: 50 mg IV qDay
• 1 year to <11 years: 100 mg IV qDay
• ≥11 years: 200 mg IV qDay; recommended daily treatment should not exceed 7 days
• If no improvement in scorbutic symptoms, retreat until resolution of scorbutic symptoms is observed
• Repeat dosing is not recommended in children and adolescents <11 years
• Also, see Administration

Charcot-Marie-Tooth Disease (Orphan)

Designated orphan indication for Charcot-Marie-Tooth disease type 1A

Orphan designated sponsor

• Murigenetics SAS; Faculte de Medecine Timone; 13005 Marseille, France

Frequency Not Defined

Flushing

Flank pain

Faintness, headache

Diarrhea, dyspepsia, nausea, vomiting

Hyperoxaluria (large doses)

When oral administration is not feasible or when malabsorption is suspected

IM preferred to IV

IV Compatibility

Compatible w/ most common diluents (dextrose solns, NS, LR, Ringer's, ½NS, dextrose-saline, dextrose-LR etc)

IV Preparation

Dilute with large volume of compatible fluid to minimize adverse reactions

IV ascorbic acid (Ascor) is supplied as a pharmacy bulk package (PBP)

Intended for dispensing of single doses to multiple patients in a pharmacy admixture program and is restricted to the preparation of admixtures for infusion

Use only in a suitable ISO Class 5 work area such as a laminar flow hood (or an equivalent clean air compounding area)

Open vials are to be used within 4 hr

Prior to administration, the final diluted solution for infusion must be isotonic (undiluted the osmolarity is ~5,900 mOsmol/L)

Calculate the osmolarity of the intended admixture for infusion

Add daily dose directly to an appropriate volume of a suitable infusion solution (eg, 5% Dextrose Injection)

Do not mix with solutions containing elemental compounds that cause reduction (eg, copper)

Final concentration of ascorbic acid admixture solution for infusion: 1-25 mg/mL

Visually inspect for particulate matter and discoloration prior to administration; solution should appear colorless to pale yellow

Immediately use as a slow IV infusion

IV Administration

Avoid rapid infusion

Infusion rate of diluted Ascor solution

• 5 months-12 months: 1.3 mg/minute
• 1-11 years: 3.3 mg/minute
• >11 years: 33 mg/minute

Oral Administration

Take with or without meals

Storage

Unopened IV vials: Store in refrigerator at 2-8°C (36-46°F); protect from light; contains no preservatives

Opened IV vials: Use within 4 hr of vial entry; discard remaining portion

Tablets: Store at room temperature at 15-30°C (59-86°F)